Investigational Study With the BD PosiFlush™ SafeScrub on NADs

NCT06604026

Status	RECRUITING
Phase	Not Applicable
Sponsor	Becton, Dickinson and Company
Enrollment	220 participants

Key Eligibility Criteria

Inclusion (3)

- Any patient (e18 years of age) in a high acuity hospital medical or surgical unit regardless of gender, with an eligible in-situ vascular access device and with a needleless access device (NAD). This includes patients who have a current VAD, whether it is newly placed or long-term access as part of their routine medical care. Eligible in-situ vascular access devices are peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs), central venous catheters (CVCs) and implanted venous access ports. Eligible NADs are stopcocks, Y-sites, and needle-free connectors.
- Expected to be available until 2 accesses are completed and for any periodic observation upto 15 min after each access.
- Able and willing to provide informed consent or legal authorized representative (LAR) authorized to give consent on behalf of the participant.

Exclusion (8)

- Any patient in whom observation might interfere with medical care or create undue hardship as determined by the patients care team.
- Patients under the age of 18.
- Patients suffering hypernatremia and fluid retention, when the administration of sodium or chloride could be clinically detrimental as determined by the study investigator.
- Patients with a known allergy to any of the followings as determined by the study investigator:
- Any of the components or materials of BD PosiFlush™ SafeScrub device or BD PosiFlush™ SP Syringe, or

... and 3 more (see full listing online)

Locations (2 total)

Ordensklinikum Linz Elisabethinen, Linz, Upper Austria, Austria
Medical University Vienna, Vienna, Austria